期刊文献+

地特胰岛素联合米格列醇治疗磺脲类继发失效2型糖尿病疗效观察 被引量:2

Clinical Observation of Insulin Determir Combined with Miglitol in Type 2 Diabetes Mellitus with Secondary Failure of Sulphonylureas
下载PDF
导出
摘要 目的:探讨地特胰岛素联合米格列醇治疗磺脲类继发性失效2型糖尿病的疗效。方法:72例患者按随机数字表法分为治疗组(A组)和对照组(B组)各36例;A组给予地特胰岛素联合米格列醇治疗,B组给予皮下注射门冬胰岛素30R,治疗12周。比较治疗前后两组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb Alc)、血糖达标率及低血糖率。结果:两组治疗前后FBG、2 h PG和Hb Alc均明显下降(P<0.05),但两组治疗后比较差异无统计学意义(P>0.05)。A组低血糖率低于B组(P<0.05)。结论:地特胰岛素联合米格列醇治疗磺脲类继发性失效2型糖尿病方便、安全、有效。 Objective: To observe the effect of insulin Determir combined with miglitol in treatment of secondary failure-to sulfonylureas in type 2 diabetes mellitus.Method: 72 cases were randomly divided into group A and group B, 36 eases of each group.The group A was treated with insulin Determir combined with Miglitol, while group B was given subcutaneous injection of insulin Aspart 3OR.Both groups were treated for 12 weeks. The fasting plasma glucose ( FBG ), 2-hour postprandial plasma glucose ( 2 h PG ), glycosylated hemoglobin ( HbAlc ), the control rate and incidence of low blood glucose before and after treatment of the two groups were compared.Result: After treatment, the FBG, 2 h PG and HbAlc of two groups were remarkably decreased, and the differences were statistically significant ( P〈0.05 ) . But there were no statistical significance between two groups after treatment ( P〉0.05 ) .And in the A group , the rate of hypoglycemia was lower than in B group ( P〈0.05 ) .Conclusion: Insulin Determir combined with Miglitol is convenient, safe and effective with secondary failure of Sulphonylureas in type 2 diabetes mellitus.
作者 李翔 祁梅
出处 《中国医学创新》 CAS 2015年第6期20-22,共3页 Medical Innovation of China
关键词 地特胰岛素 米格列醇 磺脲类继发性失效 2型糖尿病 Insulin Determir Miglitol Secondary failure of sulfonylureas Type 2 diabetes mellitus
  • 相关文献

参考文献7

二级参考文献32

  • 1杜伟奇,施秀芳,邱明艳,张文博.治疗糖尿病药物的研究进展[J].中国医院药学杂志,2005,25(1):70-72. 被引量:25
  • 2Soran H,YounisN.Insulin dctemir:a new basal insulin analogue.Diabetes Obes Metab,2006,8:26-30.
  • 3Kurtzhals P,Schaffer L,Sorens A.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.Diabetes,2000,49:999-1005.
  • 4Rosenstock J,Davies M,Home PD,et al.A randomised,52-week,treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Diabetologin,2008,51:408-416.
  • 5Wiesli P,Krayenbuhl P,Uthoff H,et al.Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime:a prospective study in patients with type 2 diabetes.Diabetologia,2009,52:1816-1819.
  • 6The Diabetes Control and Complications Research Group.Adverse events and their association with treatment regimens in the diabetes control and complications trial.Diabetes Care,1995,18:1415-1427.
  • 7Hennige AM,Sartorius T,Tschritter O,et al.Tissue selectivity of insulin detemir action in vivo.Diabetologia,2006,49:1274-1282.
  • 8Hallschmid M,Jauch-Chara K,Korn O,et al.Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.Diabetes,2010,59:1101-1107.
  • 9Klein O,Lynge J,Endahl L.Albumin-bound basal insulin analogues (insulin detemir and NN344):comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Diabet Obes Metab,2007,9:290-299.
  • 10Plank J,Bodenlenz M,Sinner F.A double-blind,randomized,dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.Diabetes Care,2005,28:1107-1112.

共引文献269

同被引文献18

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部